Advanced Non Small Cell Lung Cancer Clinical Trial
Official title:
An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Advanced Non-Small Cell Lung Cancer
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity of autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced non-small cell lung cancer (NSCLC). Patients will initially enter the study for procurement of tumour materials required to manufacture ATL001. Following manufacture of ATL001, the product will be given back to eligible patients following lymphodepletion. Patients will continue to be followed up for a minimum of 5 years, as part of a separate Long Term Follow Up Protocol, or, if the separate protocol is not available at the study site, within this protocol. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03326752 -
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
|
Phase 1 | |
| Completed |
NCT02157883 -
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
|
Phase 1 | |
| Completed |
NCT00072631 -
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT02163733 -
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06107374 -
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
|
Phase 2 | |
| Completed |
NCT01802632 -
AZD9291 First Time In Patients Ascending Dose Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06406166 -
Lifei Xiaoji Wan in Treatment of Advanced NSCLC
|
N/A | |
| Terminated |
NCT04785365 -
Long-Term Follow-Up Study of Patients Receiving ATL001
|
Phase 2 | |
| Completed |
NCT01631136 -
Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04239443 -
Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer
|
Phase 2 | |
| Completed |
NCT03452150 -
D-0316 First Time in Patients Ascending Dose Study
|
Phase 1 | |
| Completed |
NCT04144608 -
Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04755738 -
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03652857 -
Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03351361 -
Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients
|
Phase 3 | |
| Completed |
NCT02407327 -
Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
|
||
| Active, not recruiting |
NCT02143466 -
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
|
Phase 1 | |
| Recruiting |
NCT05004974 -
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05777603 -
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT04886401 -
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC
|